|
Palo Alto, CA, September 7, 2004 - Telik, Inc. (Nasdaq: TELK) announced that
company management will present an update at the Newsmakers in the Biotech
Industry Conference on Thursday, September 9, 2004 at 4:30 p.m. Eastern time
at the Millennium Broadway Hotel and Conference Center in New York City.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover,
develop and commercialize small molecule drugs to treat serious diseases.
The company's most advanced drug development candidate is TELCYTAT (TLK286),
a tumor-activated small molecule product candidate which is in Phase 3
registration trials in advanced ovarian and non-small cell lung cancer.
Telik's product candidates were discovered using its proprietary drug
discovery technology, TRAP, which enables the rapid and efficient discovery
of small molecule drug candidates. Additional information is available at www.telik.com
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2004
Press Releases2003
Press ReleasesEvents
|
